Adakveo® (crizanlizumab) – New orphan drug approval
November 15, 2019 - The FDA announced the approval of Novartis’ Adakveo (crizanlizumab), to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease (SCD).
Download PDF
